000 | 01990 a2200505 4500 | ||
---|---|---|---|
005 | 20250514004616.0 | ||
264 | 0 | _c20011204 | |
008 | 200112s 0 0 eng d | ||
022 | _a0721-832X | ||
024 | 7 |
_a10.1007/s004170100285 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aReinhard, T | |
245 | 0 | 0 |
_aSystemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial. _h[electronic resource] |
260 |
_bGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie _cJun 2001 |
||
300 |
_a367-72 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial | ||
650 | 0 | 4 | _aAdolescent |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAged, 80 and over |
650 | 0 | 4 |
_aCyclosporine _xtherapeutic use |
650 | 0 | 4 |
_aEnzyme Inhibitors _xtherapeutic use |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aGraft Rejection _xprevention & control |
650 | 0 | 4 |
_aGraft Survival _xdrug effects |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aIMP Dehydrogenase _xantagonists & inhibitors |
650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
650 | 0 | 4 | _aKeratoplasty, Penetrating |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aMycophenolic Acid _xanalogs & derivatives |
650 | 0 | 4 | _aProspective Studies |
650 | 0 | 4 | _aRisk Factors |
650 | 0 | 4 | _aSafety |
700 | 1 | _aReis, A | |
700 | 1 | _aBöhringer, D | |
700 | 1 | _aMalinowski, M | |
700 | 1 | _aVoiculescu, A | |
700 | 1 | _aHeering, P | |
700 | 1 | _aGodehardt, E | |
700 | 1 | _aSunmacher, R | |
773 | 0 |
_tGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie _gvol. 239 _gno. 5 _gp. 367-72 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1007/s004170100285 _zAvailable from publisher's website |
999 |
_c11409385 _d11409385 |